Catatonia and neuroleptic malignant syndrome in view of a psychopathological and pathophysiological overlap: A brief review;Katatónia és neuroleptikus malignus szindróma a pszichopatológiai és patofiziológiai átfedések tükrében: Rövid összefoglaló tanulmány

Neuropsychopharmacologia Hungarica

Volumn 16, Issue 1, 2014, Pages 19-28

  Zoltán, Asztalos ^a   Luca, Egervári ^b   Gábor, Andrássy ^a   Gábor, Faludi ^b   Frecska, Ede ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Catatonia; ECT; Neuroleptic malignant syndrome; Neuropathology; Pathophysiology; Psychopathology; Psychosis; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

CATATONIA; CATATONIC SCHIZOPHRENIA; ELECTROCONVULSIVE THERAPY; HUMAN; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; REVIEW; THERAPY EFFECT;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CATATONIA; DIAGNOSIS, DIFFERENTIAL; ELECTROCONVULSIVE THERAPY; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; SCHIZOPHRENIA, CATATONIC;

EID: 84897439037     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Adnet, P., Lestavel, P., Krivosic-Horber, R. (2000) Neuroleptic malignant syndrome. Br J Anaesth, 85:129-135.
2. Baykan, B., Ertas, N.K., Ertas, M., Aktekin, B., Saygi, S., Gokigit, A. (2005) Comparison of classifications of seizures: a preliminary study with 28 participants and 48 seizures. Epilepsy Behav, 6:607-612.
3. Berardi, D., Amore, M., Keck, P.E., Troia, M., Dellatti, M. (1998) Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry, 44:748-754.
4. Bush, G., Fink, M., Petrides, G., Dowling, F., Francis, A. (1996) Catatonia II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand, 93:137-143.
5. Bush, G., Fink, M., Petrides, G., Francis, A. (1996) Catatonia. Rating scale and standardized examination. Acta Psychiatr Scand, 93:129-143.
6. Caroff, S.N. (1980) The neuroleptic malignant syndrome. J Clin Psychiatry, 41:79-83.
7. Carroll, BT., Goforth, HW., Thomas, C., Ahuja, N., McDaniel, WW., Kraus, MF., Spiegel, DR., Franco, KN. et al. (2007). "Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes". J Neuropsychiatry Clin Neurosci 19 (4): 406-12.
8. Casamassima, F., Lattanzi, L., Perlis, R.H., Litta, A., Fui, E., Bonuccelli, U., Fricchione, G., Cassano, G.B. (2010) Neuroleptic malignant syndrome: further lessons from a case report. Psychosomatics, 51:349-354.
9. Choi, H.D., Kim, K.K., Koo, B.H. (2011) A case of catatonia and neuroleptic malignant syndrome probably associated with antipsychotic in Korea. Psychiatry Investig, 8:174-177.
10. Daniels, J. (2009) Catatonia: clinical aspects and neurobiological correlants. J Neuropsychiatry Clin Neurosci, 21:371-380.
11. Davis, J.M., Janicak, P.G., Sakkas, P., Gilmore, C., Wang, Z. (1991) Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convulsive Ther, 7:111-120.
12. Delay, J., Pichot, P., Lempiere, T., Blissalde, B., Peigne, F. (1960) Un neuroleptique majeur non phenothiazinique et non réserpinique, l'halopéridol, dans le traitement des psychoses. Ann Med Psychol, 18:145-152.
13. Dhosse, D.M., Wachtel, L.E. Catatonia in psychiatric illnesses. In: Fatemi, S.H., Clayton, P.J. (Eds.), The medical basis of psychiatry. Humana Press, Totowa, NJ, 2008, pp. 455-470.
14. Drevets, W., Raichle, M. (1998) Reciprocal suppression of regional cerebral blood flow during emotional versus higher cognitive processes. Cogn Emotion, 12:353-385.
15. Van Den Eede, F., Van Hecke, J., Van Dalfsen, A., Van Den Bossch, B., Cosyns, P., Sabbe, B.G.C. (2005) The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry, 20:422-429.
16. Faludi, G., Vladár, K., Mód, L.: A neuroleptikus malignus szindróma egy esete és kezelése. Gyógyszereink 37. 53-58. 1987.
17. Fink, M. (1996) Neuroleptic malignant syndrome and catatonia. Biol Psychiatry, 39:1-4.
18. Fink, M. (2001) Catatonia: syndrome or schizophrenic subtype? J Neural Transm, 108:637-644.
19. Fink, M., Taylor, M.A. (2001) The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci, 251: 8-13.
20. Fink, M. (2009) Catatonia: a syndrome appears, disappears, and is rediscovered. Can J Psychiatry, 54:437-445.
21. Fink, M., Taylor, M.A. (2003) Catatonia: A clinician's guide to diagnosis and treatment, Cambridge University Press, Cambridge, England
22. Fink, M., Taylor, M.A., Ghaziuddin, N. (2006) Catatonia in autism spectrum disorders: a medical treatment algorithm. Int Rev Neurobiol, 72:233-244.
23. Fink, M., Taylor, M.A. (2009) The catatonia syndrome: forgotten but not gone. Arch Gen Psychiatry. 66:1173-1177.
24. Fleischbacker, W.W., Unterweger, B., Kane, J.M., Hinterhuber, H. (1990) The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand, 81:3-5.
25. Francis, A., Chandragiri, S., Rizvi, S., Koch, M., Petrides, G. (2000) Is lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectr, 5:54-57.
26. Francis, A. (2010) Catatonia: diagnosis, classification and treatment. Curr Psychiatry Rep, 12:180-185.
27. Gazdag, G., Ungvari, G.S. (2011) Non-pharmacological biological therapies in schizophrenia. Neuropsychopharmacol Hung, 13:233-8.
28. Gazdag, G., Sienaert P. (2013): Diagnosing and Treating Catatonia: An Update. Curr Psychiatry Rev, Vol. 9, Nr 2, 130-135.
29. Gelenberg, A.J., Bellinghausen, B., Wojcik, J.D., Falk, W.E., Sachs, G.S. (1988) Aprospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry, 145:517-518.
30. Hermesh, H., Aizenberg, D., Weizman, A. (1987) A successful electroconvulsive treatment of neuroleptic malignant syndrome. Acta Psychiatr Scand, 75:237-239.
31. Jauss, M., Krack, P., Franz, M., Klett, R., Gallhofer, B., Dorndorf, W. (1996) Imaging of dopamine receptors with 123I iodobenzaminde single-photon emission-computed tomography in neuroleptic malignant syndrome. Mov Disord, 11:726-728.
32. Jueptner, M., Stephan, K.M., Brooks, D., Passingham, R. (1997) Anatomy of motor learning. Frontal cortex and attention to action. J Neurophysiol, 77:1313-1324.
33. Keck, P.E., Harrisson, G., Pope, J.R., McElroy, S.L. (1991) Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry, 148:880-882.
34. Keck, P.E., Pope, H., Cohen, B.M., McElroy, S.L., Nierenberg, A.A. (1989) Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry, 46:914-918.
35. Koch, M., Chandragiri, S., Rizvi, S., Petrides, G., Francis, A. (2000) Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry, 41:73-75.
36. Lauterbach, E. (1998) Catatonic-like events after valproic acid with risperidone and sertraline. Neuropsychiatry Neuropsychol Behav Neurol, 11:157-163.
37. Luchini, F., Lattanzi, L., Bartolommei, N., Cosentino, L., Litta, A., Kansky, C., Mauri, M., Cassano, G.B., Fagiolini, A., Casamassima, F. (2013) Catatonia and neuroleptic malignant syndrome: two disorders on a same spectrum? Four case reports. J Nerv Ment Dis, 201:36-42.
38. Mall, G.D., Hake, L., Benjamin, A.B., Adityanjee, A. (2008) Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: case report. J Clin Psychopharmacol, 28:572-573.
39. Mann, S.C., Caroff, S.N., Fricchione, G., Campbell, C. (2000) Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann, 30:363-374.
40. Mastermann, D., Cummings, J.L. (1997) Frontal-subcortical circuits: the anatomic basis of executive, social and motivated behavior. J Psychopharmacol, 11:107-114.
41. Nisijima, K., Ishiguro, T. (1995) Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res, 29:233-244.
42. Northoff, G., Wenke, J., Krill, W., Pflug, B. (1995) Ball experiments in 32 acute akinetic catatonic patients: deficits of internal initiation and generation of movements. Mov Disord, 10:589-595.
43. Northoff, G., Demisch, L., Wenke, J., Pflug, B. (1996) Plasma homovanillic acid concentration in catatonia. Biol Psychiatry, 39:436-443.
44. Northoff, G., Eckert, J., Fritze, J. (1997) Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA-antagonist amantadine. J Neurol Neurosurg Psychiatry, 62:404-406.
45. Northoff, G., Krill, W., Eckert, J., Russ, M., Pflug, B. (1998) Subjective experience of akinesia in catatonia and Parkinson's disease. Cogn Neuropsychiatry, 3:161-178.
46. Northoff, G., Braus, D.F., Russ, M., Eckert, J., Bogerts, B., Henn, F. (1999) Reduced activation and altered laterality in two neuroleptic-naive catatonic patients during a motor task in functional MRI. Psychol Med, 29:997-1002.
47. Northoff, G., Koch, A., Wenke, J., Eckert, J., Pflug, B., Bogerts, B. (1999) Catatonia as a psychomotor disease: a rating scale, subtypes, and extrapyramidal motor symptoms. Mov Disord, 14:404-416.
48. Northoff, G., Steinke, R., Czcervenka, C., Ulrich, S., Otto, H.J., Bogerts, B. (1999) Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. J Neurol Neurosurg Psychiatry, 67:445-451.
49. Northoff, G., Steinke, R., Nagel, D., Otto, H.J., Bogerts, B. (2000) Right lower prefrontoparietal cortical dysfunction in akinetic catatonia: a combined study of neuropsychology and regional cerebral blood flow. Psychol Med, 30:583-596.
50. Northoff, G. (2002) Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm, 109:1453-1467.
51. Paparrigopoulos, T., Tzavellas, E., Ferentinos, P., Mourikis, I., Liappas, J. (2009) Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry, 10:70-73.
52. Petrides, G., Divadeenam, K., Bush, G., Francis, A. (1997) Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia. Biol Psychiatry, 42:375-381.
53. Petrides, G., Malur, C., Fink, M. Convulsive therapy. In: Caroff, S.N., Mann, S.C., Francis, A., Fricchione, G.L. (Eds.), Catatonia: From psychopathology to neurobiology. American Psychiatric Press, Washington, DC, 2004, pp. 151-160.
54. Philibert, R., Adam, L., Frank, F., Doebbeling, C. (2001) Olanzapine usage associated with neuroleptic malignant syndrome. Psychosomatics, 42:528-529.
55. Réthelyi, J. (2011): Diagnosing schizophrenia: from Bleuler to DSM-V. Neuropsychopharmacol Hung, 13:193-203.
56. Rosebush, P.I., Hildebrand, A.M., Furlong, B.G., Mazurek, M.F. (1990) Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry, 51:357-362.
57. Rosebush, P.I., Mazurek, M.F. (1999) Catatonia: re-awakening to a forgotten disorder. Mov Disord, 14:395-397.
58. Shalev, A., Hermesh, H., Munitz, H. (1989) Mortality from neuroleptic malignant syndrome. J Clin Psychiatry, 50:18-25.
59. Sienaert, P., Rooseleer, J., De Fruyt, J. (2011) Measuring catatonia: a systematic review of rating scales. J Affect Disord, 135:1-9.
60. Strawn, J.R., Keck, P.E., Caroff, S.N. (2007) Neuroleptic malignant syndrome. Am J Psychiatry, 164:870-876.
61. Susman, V.L. (2001) Clinical management of neuroleptic malignant syndrome. Psychiatr Q, 72:325-336.
62. Taylor, M.A., Fink, M. (2003) Catatonia in psychiatric classification: a home of its own. Am J Psychiatry, 160:1233-1241.
63. Trollor, J.N., Sachdev, P.S. (1999) Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry, 33:650-659.